The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting <i>HER2</i> -mutant NSCLC: a bench-to-bedside review

Zongertinib is the first oral TKI approved for <i>HER2</i>-mutant NSCLC and will provide patients with a convenient, tolerable and effective treatment option in an area of significant unmet need. Next steps include its potential transition to a first-line setting, identification of additional indications, and development of novel combination regimens.

Authors

Institutions

Publication Details

Journal
Expert Review of Anticancer Therapy
Published
2026-02-05
DOI
https://doi.org/10.1080/14737140.2026.2623059
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2 -mutant NSCLC: a bench-to-bedside review

T. Yoshida, E. Smit, Birgit Wilding, Jon Zugazagoitia et al.
Expert Review of Anticancer Therapy
Lung Cancer Treatments and Mutations
article

The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2 -mutant NSCLC: a bench-to-bedside review

T. Yoshida, E. Smit, Birgit Wilding, Jon Zugazagoitia, Popat Sanjay, Yan Yu, David Planchard, Petros Christopoulos
article en

Abstract

Zongertinib is the first oral TKI approved for <i>HER2</i>-mutant NSCLC and will provide patients with a convenient, tolerable and effective treatment option in an area of significant unmet need. Next steps include its potential transition to a first-line setting, identification of additional indications, and development of novel combination regimens.

Expert Review of Anticancer Therapy
Royal Marsden NHS Foundation Trust (GB), Boehringer Ingelheim (Germany) (DE), The University of Texas MD Anderson Cancer Center (US), Harbin Medical University (CN), Heidelberg University (DE), Université Paris-Saclay (FR), Leiden University Medical Center (NL), Union for International Cancer Control (CH), University Hospital Heidelberg (DE), Research Institute Hospital 12 de Octubre (ES), National Cancer Center (US), Institute of Cancer Research (CA), Third Affiliated Hospital of Harbin Medical University (CN), National Center for Tumor Diseases (DE), German Center for Lung Research (DE)
Good health and well-being
Openalex Percentile: Top 67%
Lung Cancer Treatments and Mutations
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting <i>HER2</i> -mutant NSCLC: a bench-to-bedside review — T. Yoshida, E. Smit, et al. · Expert Review of Anticancer Therapy (2026) | TGRS Research Map | TGRS